U.S. Markets open in 2 hrs 29 mins
  • S&P Futures

    3,675.50
    +21.25 (+0.58%)
     
  • Dow Futures

    29,419.00
    +134.00 (+0.46%)
     
  • Nasdaq Futures

    11,287.50
    +59.25 (+0.53%)
     
  • Russell 2000 Futures

    1,695.00
    +12.90 (+0.77%)
     
  • Crude Oil

    81.44
    +0.21 (+0.26%)
     
  • Gold

    1,674.20
    +5.60 (+0.34%)
     
  • Silver

    19.00
    +0.28 (+1.51%)
     
  • EUR/USD

    0.9764
    -0.0056 (-0.5663%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.03
    +0.85 (+2.82%)
     
  • GBP/USD

    1.1066
    -0.0057 (-0.5157%)
     
  • USD/JPY

    144.4700
    +0.0270 (+0.0187%)
     
  • BTC-USD

    19,476.96
    +19.64 (+0.10%)
     
  • CMC Crypto 200

    445.24
    -0.74 (-0.17%)
     
  • FTSE 100

    6,924.93
    +43.34 (+0.63%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Analyst Sees This 'Specialty Pharma' Stock Stuck Until Prescription Trends Improve

·2 min read
  • Last week, Collegium Pharmaceutical Inc (NASDAQ: COLLreported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates.

  • HC Wainwright has downgraded the stock to Neutral with no price target vs. prior Buy with a $29 target.

  • "We applaud the recent financial results but have been disappointed by Xtampza and Belbuca Rx trends, which are below our projections, down slightly Y/Y, and trajectories currently flat at best," the analyst writes.

  • The analyst believes that 2022 guidance is achievable but thinks investors care most about 2023 and beyond and will remain in "show me" mode for Rx growth and the Xtampza net price jump.

  • The analyst notes that acquired Belbuca was surprisingly strong, beating estimates by 14-15% on a step-up in value-per-Rx as Collegium modified legacy co-pay assistance.

  • Xtampza also beat despite light Rx, with better than guided gross-to-net discounts (GTNs), but management reiterates the expected 2H GTN worsening. HC Wainwright models Xtampza net price up ~40% in 2023.

  • M&A remains a top priority, with Collegium looking for commercial assets with over $150 million potential.

  • COLL trades at cheap multiples, but Wainwright notes Nucynta and Belbuca 2025 and 2027 patent cliffs.

  • Belbuca generic 2nd-challenger Alvogen—currently patent-ruling blocked until end-2032—could have its appeal heard by year-end, raising new investor concerns.

  • Price Action: COLL shares are down 6.07% at $18.88 during the market session on the last check Monday.

Latest Ratings for COLL

Date

Firm

Action

From

To

Feb 2022

Piper Sandler

Maintains

Overweight

Feb 2022

HC Wainwright & Co.

Maintains

Buy

Feb 2022

Needham

Maintains

Buy

View More Analyst Ratings for COLL

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.